Introduction
The vasculature is a unique target organ for gene therapy. It offers a number of benefits for gene transfer, the most significant being the ease of accessibility and transfer of the transgene to a specific site or to the entire vasculature. Transgene products may also be secreted locally or into the bloodstream for a systemic effect. 1 In animal models, vascular gene transfer has been used successfully to alter neointimal formation and vasomotor reactivity and to stimulate angiogenesis. 2, 3 However, the vast majority of gene therapy protocols is involved in cancer therapy. Strategies currently under clinical investigation for the treatment of cancer include the study of genes that activate or encode cytotoxins and immune modulators. 4, 5 The success of non-surgical methods of cancer treatment is dependent on the supply of blood to the tumour. It has been reported that damage to a single vessel can cause the death of thousands of dependent tumour cells and only a small number of endothelial cells need to be affected to disrupt a vessel. 6 It would therefore be advantageous to alter the tumour blood supply locally without causing damage to normal vasculature.
Nitric oxide (NO) is a potent biological mediator with diverse physiological and pathophysiological functions. It can act as a vasodilator, neurotransmitter, antimicrobial effector molecule and immunomodulator. 7 It is produced by one of three distinct isoforms of the nitric oxide synthase (NOS) gene. The inducible isoform of the enzyme (iNOS) produces large quantities of NO in a Ca were then transfected with the WAF1/iNOS construct; this gave five-fold induction of iNOS protein after a dose of 4 Gy.
The transfected artery was also tested functionally for relaxation, indicative of NO production. One hour after exposure to 4 Gy there was a significant (65%) relaxation of artery segments that had been preconstricted with phenylephrine. This could be partially reversed by the NOS inhibitor nitro-L-arginine. This study demonstrates that we can regulate vascular tone using an X-ray inducible promoter. Gene Therapy (2000) 7, 1126-1131. pendent manner. Elevated levels of iNOS have been detected in a number of human and mammalian tumour tissues, [8] [9] [10] although more than one cell type may be expressing the gene. Increased expression of NOS may facilitate the delivery of oxygen and nutrients through the dilated microvessels to the rapidly proliferating tumour cells.
The main limitation with gene therapy protocols is lack of target specificity. A number of strategies have been devised to localise therapy to the desired area; these include the use of tissue-specific receptors 11 and tissuespecific enhancers 12 to control expression at the transcription level. Alternatively, inducible promoters can be employed to modulate gene expression transcriptionally. A number of inducible systems have been developed: a tetracycline-controlled expression system, 13 and a progesterone anatagonist-regulated promoter.
14,15 Weichselbaum et al 16 described an inducible system using radiation-responsive consensus sequences from the early growth response (EGR) gene promoter ligated upstream from the TNF-␣ gene. This inducible system was used in studies that reported an increase in intratumour production of TNF-␣ when nude mice were injected with the Egr-TNF construct and exposed to radiation. 17 More recently it has been reported that the EGR-1 promoter can be activated by the more clinically relevant dose of 2 Gy. 18 A number of genes have been reported to be induced by ionising radiation. 19 We now describe the use of the promoter for the X-ray inducible gene, WAF1 20 to regulate iNOS gene expression in the vasculature. Modulating the human vasculature in this way may ultimately aid in the delivery of chemotherapeutic agents through vasodilated vessels, or enhance oxygen delivery to reduce the number of radioresistant hypoxic cells.
Results
In vitro transfections with WAF1/pEGFP HMEC-1 cells transfected with the WAF1/pEGFP reporter vector were irradiated with various doses of Xrays (0, 2, 4 and 6 Gy). At certain time-points after irradiation (0, 30 min, 1, 2, 4, 8 and 24 h), samples were extracted for Western blot analysis. A dose of 2 Gy failed to induce WAF1-mediated GFP gene activation, however in cells exposed to 4 Gy of ionising radiation GFP levels rose rapidly (Figure 1) , with induction appearing after 1 h and becoming statistically significant compared with background levels after 2 h (P Ͻ 0.05, analysis of variance). Twenty-four hours after irradiation, levels of GFP were 9.6 times higher than in unirradiated cells. Cells exposed to 6 Gy also showed a rise in GFP levels along the time course, with levels of GFP after 24 h being 6.6 times higher than in unirradiated cells.
Ex vivo transfection of rat tail artery with WAF1/pEGFP
The feasibility of transfecting rat tail artery in an ex vivo perfusion apparatus was tested using the WAF1/pEGFP reporter vector. The artery was transfected for 2 h, irradiated and at various time-points (0, 1, 4 and 8 h) after treatment a 1-cm 3 section was removed for analysis of GFP levels using Western blotting. Analysis could only be carried out up to a maximum of 8 h after irradiation due to a finite life span of the artery ex vivo. Induction of GFP protein was observed after both 4 and 6 Gy ( Figure 2 ). By 8 h after irradiation GFP levels increased 4.5-and eight-fold, respectively. This experiment established the principle that this perfusion apparatus could be used for future transfections using the WAF1/iNOS construct. Ex vivo transfection of rat tail artery with WAF1/iNOS construct A section of rat tail artery was cannulated and placed on a perfusion apparatus. Its responsiveness was tested by perfusion with phenylephrine (PE). The artery was then transfected with the WAF1/iNOS vector, exposed to 4 Gy X-rays and its responsiveness to PE tested again at various time-points. Figure 3 shows a typical computer trace of changes in pressure associated with testing the responsiveness of the artery at various times during the experiment. At each of the time points (A, B, C, D and E) the artery was perfused with 2 × 10 −5 m PE in Krebs. During the initial test at time point A the artery had a normal contractile response to PE. The artery was then transfected, subjected to 4 Gy X-rays and tested again, with a normal response being observed (B). Time point C represents a responsiveness test 30 min after irradiation. The contractile response of the artery was reduced dramatically. At time-point D, 60 min after exposure to X-rays, the artery was fully relaxed and exhibited almost no response to PE. The artery was then perfused for 1 h with the iNOS inhibitor nitro-l-arginine and tested again with PE (E). This resulted in an increased, though not fully restored level of constriction. On average (Figure 4) , a significant decrease in responsiveness to PE was observed after 30 min, and by 60 min after irradiation constriction of the artery was only 35% that of the control. Perfusion for 1 h in the NOS inhibitor nitro-l-arginine resulted in constriction levels rising to 75% of control levels.
Western blot analysis of homogenised artery samples taken at various time-points (0, 1, 4 and 8 h) after treatment with X-rays showed increased levels of iNOS protein at all doses ( Figure 5 ). By 8 h after irradiation with 2 Gy, iNOS protein levels were 3.7 times above control levels, while after exposure to 4 and 6 Gy protein levels Gene Therapy increased by 5.3-and 3.9-fold, respectively. Although the unirradiated artery sample had a slightly higher level of iNOS protein than the control, which was neither transfected nor irradiated, this was not found to be statistically significant (P Ͼ 0.05 (ANOVA)).
Discussion
This study was designed to investigate the feasibility and effectiveness of vascular human iNOS gene transfer controlled by an inducible promoter. We explored the prospect of using the radiation-inducible WAF1 promoter to control gene expression in endothelial cells in vitro and ex vivo in rat tail artery. We have demonstrated induced gene expression at clinically relevant radiation doses. Artery tissue transfected with the vector construct, but not irradiated, showed no statistically significant increase in the level of iNOS (compared with non-transfected arteries). This suggests that the WAF1 promoter was minimally 'leaky' within our system.
It is obvious from our data that there is no linear dose response relationship for WAF1 regulation of gene expression in our systems. Differences in response of WAF1 between the in vitro human endothelial cells and the ex vivo rat artery system may be explained in part by tissue-and species-specific effects; there may be a differ-ence in the levels of transcription factors responsible for regulating the WAF1 promoter.
Following an X-ray dose of 4 Gy, the WAF1 promoter induced similar levels of GFP and iNOS by a factor of 4.5-and 5.3-fold, respectively. However, in the ex vivo artery system, WAF1 induced GFP more effectively than iNOS following a dose of 6 Gy, and yet at 2 Gy WAF1 effectively induced iNOS, but failed to induce GFP. It has been reported that NO positively regulates the WAF1 promoter. 21 Low levels of NO generated following irradiation of the arteries at 2 Gy may, therefore, further activate the WAF1 promoter via a positive feedback loop. An X-ray dose of 6 Gy gave variable levels of induction, dependent on the tissue system used and also on the therapeutic gene. This effect may be due to regulation of the WAF1 promoter via NO shifting the dose response relationship such that the dose of 6 Gy fell beyond the optimum for activation of the promoter.
Although the WAF1 promoter is not as sophisticated as some of the more recently developed composite promoters, 22 it has provided sufficient levels of gene expression to generate marked physiological effects. We achieved a 65% relaxation in arteries irradiated with 4 Gy of X-rays. Although it is not possible to determine the amount of NO being released within the artery in our study, the same level of relaxation in this system required 5 × 10 −7 mol/l of the nitric oxide donor sodium nitroprusside. 23 We could therefore estimate that we were generating an equivalent amount of NO in our study.
The use of liposomes for transfections has the intrinsic difficulty that the percentage of cells successfully transfected is low. In an in vitro situation, using the GFP reporter vector attached to a constitutive promoter and visually estimating the number of cells transfected, we achieved a 23-27% transfection efficiency. However, we would expect the percentage of cells transfected in the ex vivo situation to be much lower. Using a retroviral vector, Tzeng et al 24 reported a 1% transfection efficiency of human iNOS into vascular cells. Whilst for other gene therapy applications this low level of transfection efficiency would prove disastrous, for gene therapy involving the iNOS gene this does not represent a problem. Although the number of cells secreting the transgene product may be low, the vasoactive agent, NO is highly diffusible in solution and creates a 'field effect' around secreting cells. 25 Therefore, even if iNOS is expressed in only a few cells, a wide field of cells could be exposed to NO.
Tzeng et al 26 reported on the requirement for an exogenous supply of the NOS co-factor tetrahydrobiopterin (BH 4 ) for the successful production of NO after iNOS gene transfer in vascular smooth muscle cells. Studies within our laboratory (Worthington, unpublished data) indicate that an exogenous BH 4 supply is required for successful NO production in ex vivo vessel transfections, and so it was added as a co-factor in our perfusion studies.
This study demonstrates 'proof of principle' that we can regulate vascular tone using an X-ray inducible promoter. We have shown that the human iNOS gene can be transfected into vessels ex vivo with expression being controlled by the WAF1 promoter to elicit a physiological response. The induced expression of iNOS and subsequent production of NO resulted in a much reduced response to the vasoconstrictor PE.
Gene Therapy
This approach to cancer gene therapy has a number of applications. iNOS is found in elevated levels in mammalian tumours [8] [9] [10] and employing an antisense gene therapy approach could lead to a constriction in tumour vessels and subsequent decrease in oxygenation levels. This artificially hypoxic tumour environment could then be targeted with any novel bioreductive drugs (eg AQ4N 27 ) subsequently shown to be effective in the clinic. It may be more advantageous to stimulate the tumour to express increased levels of iNOS. Transfecting the tumour vessels with iNOS attached to an X-ray inducible promoter and increasing blood flow with a primary dose of radiation may increase oxygenation within the tumour, allowing a greater level of cell kill by subsequent therapeutic doses. By introducing the iNOS gene linked to an X-ray inducible promoter, we could selectively induce the gene, increasing blood flow in the tumour microvasculature, and use a fractionated dosing regime to achieve maximum tumour cell kill with minimum damage to the surrounding tissue. Alternatively, chemotherapeutic agents could be delivered to the tumour through the dilated vessels.
We have shown that we can achieve significantly enhanced levels (3.7-fold) of iNOS in arterial tissue following a dose of 2 Gy. It remains to be seen whether or not this level of induction will be sufficient to produce a therapeutic advantage. We believe that fractions of 2 Gy may be sufficient for treatment because NO generated from the radiation dose will further induce the WAF1 promoter, 21 resulting in increased levels of iNOS being expressed, which will persist and accumulate during a course of therapy. An alternative therapeutic regime would be to use an initial priming dose of 4 Gy, followed by subsequent 2 Gy fractions.
As an additional benefit of this approach, the increased levels of NO may act in a cytotoxic fashion. For this application, however, it may be necessary to incorporate another layer of specificity into the vector. In targeting the tumour only, we could exploit the hypoxic environment within the tumour, choosing an enhancer element which is specific for hypoxia. Studies within our laboratory have shown that the WAF1 promoter is upregulated in hypoxic conditions (Murray, personal communication). Since we wish to target only vasculature an obvious choice for an additional enhancer element would be the promoter region of the vascular endothelial growth factor (VEGF) receptor (flt-1) 28 which is expressed in proliferating endothelial cells.
Promoters incorporating a radiation-sensitive element have the potential to regulate the tumour microenvironment in a manner that enhances therapy. We have demonstrated that large changes in vascular tone can be achieved even with a relatively simple system. Further development in tumour systems is currently underway.
Materials and methods
Cell culture Human micro-vascular endothelial cells HMEC-1 29 were routinely maintained in MCDB131 medium (Gibco BRL, Paisley, UK) supplemented with foetal bovine serum (10%) (Globepharm, Surrey, UK), endothelial growth factor (10 ng/ml) (Sigma, Poole, UK), hydrocortisone (1 l/ml) (Sigma) and l-glutamine (10 mm) (Gibco BRL).
Cells were grown as monolayers in tissue culture flasks at 37°C under 5% CO 2 /95% air and passaged every 3-4 days to maintain exponential growth.
WAF1/pEGFP reporter vector
The WAF1 promoter (B Vogelstein, Johns Hopkins Oncology Center, Baltimore, MD, USA) was cloned into the XhoI site of the pEGFP reporter vector (Clontech, Basingstoke, UK).
WAF1/iNOS vector iNOS cDNA (T Billiar, School of Medicine, Pittsburgh, PA, USA) was cloned into the KpnI-NotI restriction sites of the pcDNA3.1+ vector (Invitrogen, Groningen, The Netherlands). The WAF1 promoter was blunt ended using Klenow and ligated into the blunt-ended pcDNA3.1 vector after removal of the CMV promoter using NheI and NruI.
In vitro transfections HMEC-1 cells (1 × 10 5 ) were seeded into 2.5-cm Petri dishes (Nunc, Paisley, UK). After 12 h, the cells were transfected with the WAF1/pEGFP reporter vector using Lipofectin (Gibco BRL) according to the manufacturer's instructions. Forty-eight hours later, cells were irradiated with 0, 2, 4 or 6 Gy X-rays using a Siemens (Mü nchen, Germany) Stabilipan X-ray machine operated at 300 kV and a dose rate of 2.6 Gy/min. After irradiation, cells were washed several times with phosphate-buffered saline (PBS) and then harvested for protein analysis.
Preparation of rat tail artery specimens Normotensive adult male Wistar rats (250-350 g) were killed by cervical dislocation. The dorsal surface of the tail was marked, then removed. The skin was cut to one side of the mid-line, released from underlying connective tissue and pinned back. The connective tissue at the edge of the muscle block was cut to reveal the artery beneath. A plastic cannula filled with Kreb's solution was introduced into the artery and secured with suture. The segments of tail artery were placed on an apparatus that allowed internal and external perfusion. 30 The Krebs' perfusate was forced through the artery preparations at 2.0 ml/min using a peristaltic pump (Gilson M312, Ohio, USA). The output from the differential pressure transducer (0-5 psi) was connected to a MacLab type 8e A/D converter and then to a Macintosh LCII computer for data storage and subsequent analysis.
Ex vivo transfections of rat tail artery
Responsiveness of the artery was tested by perfusion with 2 × 10 −5 m of the vasoconstrictor phenylephrine (PE) (Sigma) at a concentration of 20 m. This concentration had been used in our previous studies and yielded maximal contractions. Transfections were carried out using Tfx-50 reagent (Promega, Dublin, Ireland). 25 g of the WAF1/pEGFP or WAF1/iNOS/pcDNA3.1 constructs was circulated through the artery in Krebs' solution. After 2 h transfection, the artery was removed from the apparatus and irradiated with 0, 2, 4 or 6 Gy. The artery was then reconnected to the perfusion apparatus and reactivity to phenylephrine assessed. When the WAF1/iNOS/pcDNA3.1 construct was used, the artery was perfused in Krebs' supplemented with tetrahydrobiopterin (Sigma). At various time-points a 1-cm 3 section was lysed for protein analysis. Three independent experiments were performed and the mean results reported ± 1 s.e.
Western blotting
Samples for protein analysis were extracted by lysing with laemmli buffer (Sigma). Protein concentration was measured using the BioRad Protein Assay (BioRad, Munich, Germany). 30 g of each sample was electrophoresed through a 1% SDS-polyacrylamide gel, transferred to nitrocellulose membrane (Hybond C, Amersham, UK) and probed with a mouse monoclonal anti-GFP antibody (Clontech) or rabbit monoclonal anti-iNOS (Transduction Laboratories, Lexington, KY, USA). Levels of gene expression were assessed using an ECL detection kit (Amersham). A Hoefer Scanning Densitometer was used with Hoefer Analysis software (Hoefer, San Francisco, CA, USA) to assess the intensity of each band on the autoradiograph. Three independent experiments were carried out and the mean result reported ± 1 s.e.
